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a b s t r a c t
Background: The gene KCNE1 encodes the β-subunit of cardiac voltage-gated Kþ channels and causes
long QT syndrome (LQTS). LQTS is characterized by the prolongation of QT interval and lethal
arrhythmias such as torsade de pointes (TdP). A KCNE1 polymorphism, D85N, has been shown to modify
the phenotype of LQTS through a loss-of-function effect on both KCNQ1 and KCNH2 channels when co-
expressed and reconstituted in a heterologous expression system.
Methods: A screening for the D85N polymorphism was performed in 355 LQTS families with mutations
in KCNQ1, KCNH2, or SCN5A. Among the probands who had a heterozygous status with the polymorph-
ism, we focused on a family with a KCNH2 mutation (E58K), a N-terminal missense mutation, and
examined the clinical signiﬁcance of this polymorphism. We also conducted biophysical assays to analyze
the effect of the polymorphism in mammalian cells.
Results: In 355 probands, we found 14 probands (3.9%) who had a heterozygous compound status with the
D85N polymorphism. In the family with a KCNE1-D85N polymorphism and a KCNH2-E58K mutation, the
proband and her daughter carried both the KCNH2 mutation and the KCNE1-D85N polymorphism. They
experienced repetitive syncope and TdP. Two sons of the proband had either KCNH2-E58K mutation or KCNE1-
D85N, but were asymptomatic. Biophysical assays of KCNE1-D85Nwith KCNH2-E58K variants produced a larger
reduction in the reconstituted IKr currents compared to co-expression with wild-type KCNE1.
Conclusions: The KCNE1-D85N polymorphism modiﬁed the clinical features of LQTS patients.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Long QT syndrome (LQTS) is characterized by cardiac repolarization
abnormalities that lead to TdP, syncope, and sudden cardiac death [1].
The disease is genetically heterogeneous and caused by mutations in
410 genes, including KCNH2 and KCNE1 [2–4]. In LQTS probands with
heterozygous genetic variants, compound mutations usually exacer-
bate the disease severity compared to other family members who
carry a single mutation [5–7]. Previously, the coexistence of the single
nucleotide polymorphism (SNP) KCNH2-K897T with the latent KCNH2
mutation A1116V was shown to modify the clinical symptoms [8].
A KCNE1 C-terminal polymorphism, D85N, has been found in the
normal population. The sequence, a nucleotide replacement from G
to A at 253, causes an amino acid change from aspartic acid to
asparagine at position 85 [9]. The allele frequency of the poly-
morphism is reported to be 0.7% in apparently healthy Asians [10].
Paulussen et al. demonstrated that the allele frequency of the same
variant among Europeans is 5% in drug-induced LQTS patients who
experienced TdP, but 0% in the control population [11]. More
recently, we demonstrated that the D85N allele frequency is 0.8%
among apparently healthy Japanese individuals and that it is
signiﬁcantly higher among clinically diagnosed LQTS probands
(3.9%) [9]. In a patch-clamp experiment using a heterologous
expression system in a mammalian cell line, KCNE1-D85N was
found to reduce the current densities in KCNQ1/KCNE1 channels (IKs)
and KCNH2/KCNE1 channels (IKr) by 28% and 31%, respectively [9].
In the present study, we screened for the D85N polymorphism
in 355 LQTS probands in which we could identify a mutation in
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KCNQ1, KCNH2, or SCN5A, and found 14 patients that carried the
polymorphism in addition to a single pathologic LQTS-related gene
mutation. Among them, in a family with KCNH2-E58K, D85N
appeared to modulate the phenotype of family members. In order
to clarify the phenotype–genotype correlation, we then conducted
functional assays of the variants by using a heterologous expres-
sion system in Chinese hamster ovary (CHO) cells.
2. Material and methods
2.1. Genetic analysis
The cohort of this study was 355 LQTS probands who were
identiﬁed as having mutations in KCNQ1, KCNH2, or SCN5A and
their family members. Genetic analysis was performed after
obtaining written informed consent in accordance with the study
protocol approved by our institutional ethics committees. In
addition to the 3 genes listed above, genetic screening for KCNE1
was performed by single strand conformation polymorphism or
denaturing high-performance liquid chromatography using a
WAVE System Model 3500 (Transgenomic, Omaha, NE, USA).
Abnormal conformers were ampliﬁed by polymerase chain reac-
tion (PCR). Sequencing was performed with an ABI PRISM3130
DNA sequencer (Applied Biosystems, Wellesley, MA, USA).
2.2. Mutagenesis
Complementary deoxyribonucleic acid (cDNA) for human KCNE1
(GenBank M26685) was kindly provided by Dr. J. Barhanin (Institut de
Pharmacologie Moléculaire et Cellulaire, CNRS, Valbonne, France) and
was subcloned into a pIRES-CD8 vector. cDNA for human KCNH2
(GenBank AF363636) was kindly donated by Dr. M. Sanguinetti (Uni-
versity of Utah, Salt Lake City, UT, USA) and was subcloned into a pRc-
CMV vector. A KCNE1-D85N variant was constructed using a Quik
Change II XL Site-Directed Mutagenesis Kit, according to the manufac-
turer's instructions (Stratagene, La Jolla, California, USA). A KCNH2
mutation (E58K) was constructed by overlap-extension PCR. Nucleo-
tide sequence analysis was performed on each variant construct before
the expression study to conﬁrm their sequences.
2.3. Cell transfection
CHO cells were maintained at 37 1C in Dulbecco's modiﬁed
Eagle medium and Ham's F12 nutritional mixture (Gibco-BRL,
Rockville, Maryland, USA) containing 10% fetal bovine serum
supplemented with 1% penicillin and 1% streptomycin. Wild-type
(WT) and/or variant KCNH2, and WT and/or variant KCNE1 clones
were transiently expressed in CHO cells by using the Lipofecta-
mine method according to the manufacturer's instructions (Invi-
trogen, Carlsbad, California, USA).
To identify the cells that were positive for KCNH2 expression, CHO
cells were co-transfected with 0.5–1 μg of the pRc-CMV/KCNH2 vector
and 0.5 μg of a pEGFP-N1/CMV vector. About 48–72 h after transfec-
tion, green ﬂuorescent protein (GFP) positive cells and anti-CD8
antibody-coated bead (Dynabeads CD8; Dynal Biotech, Oslo, Norway)
decorated cells were used for the patch-clamp study.
2.4. Electrophysiological assays
Whole-cell conﬁguration of the patch-clamp technique was
employed to record membrane currents at 37 1C with an EPC-8
patch-clamp ampliﬁer (HEKA, Lambrecht, Germany). Pipette resis-
tance ranged from 2.5 to 4 MΩ when ﬁlled with pipette solutions,
as described in the following text. The series resistance was
electronically compensated for at 70–85%. The extracellular
solution contained (mmol/l): 140 NaCl, 0.33 NaH2PO4, 5.4 KCl,
1.8 CaCl2, 0.5 MgCl2, 5.5 glucose, and 5 HEPES and the pH was
adjusted to 7.4 with NaOH. The internal (pipette) solution con-
tained (mmol/l): 70 potassium aspartate, 70 KOH, 40 KCl, 10
KH2PO4, 1 Mg2SO4, 3 Na2-ATP, 0.1 Li2-GTP, 5 EGTA, and 5 HEPES
and the pH was adjusted to 7.2 with KOH.
KCNH2/KCNE1-encoded currents were elicited by depolarizing
pulses from a holding potential of 80 mV to test potentials
between 60 and þ50 mV (with a 10-mV step increment), and
then repolarized to 60 mV to measure tail currents. Current
densities (pA/pF) were calculated for each cell studied by normal-
izing peak tail current amplitude to cell capacitance (Cm). The Cm
was calculated by ﬁtting a single exponential function to the decay
phase of the transient capacitive current in response to 75 mV
voltage steps (20 ms) from a holding potential of –50 mV. The
liquid junction potential between the test solution and the pipette
solution was measured as approximately 10 mV and was cor-
rected. Data were collected and analyzed using Patch master and
Igor Pro (WaveMetrics, Lake Oswego, Oregon, USA).
2.5. Data analyses
The voltage-dependence of current activation was determined
by ﬁtting the normalized tail current (Itail) vs. test potential (Vt) to
Fig. 1. Clinical Characteristics. A: Pedigree structures as well as phenotypic and
genotypic information and electrocardiogram (V5) data for family members of the
proband. Males and females are represented as squares and circles, respectively.
Genotypes are shown on the right side of the symbols, and the presence of variants
is indicated as shown in the inset. Phenotypes are shown in the left half of symbols.
Filled symbols indicate symptomatic cases. Individuals with uncertain genotype and
phenotype are indicated by a gray color. Deceased family members are indicated by
symbols with slashes. PPM, post pacemaker implantation; SCD, sudden cardiac death. B:
(a) The DNA sequence of D85N KCNE1; part of the nucleotide sequence of the KCNE1
showing a G to A transition at codon 253 leading to an amino acid substitution of
aspartic acid for asparagine at position 85. (b) The DNA sequence of E58K KCNH2; part of
the nucleotide sequence of the KCNH2 showing a G to A transition at codon 172 leading
to an amino acid substitution of glutamine for lysine at position 58.
K. Hasegawa et al. / Journal of Arrhythmia 30 (2014) 161–166162
Boltzmann's function:
Itail ¼ 1=ð1þexp½ðV0:5–VtÞ=kÞ;
where V0.5 is the voltage at which the current is half-activated and
k is the slope factor. Time constants for deactivation (τfast and τslow)
were obtained by ﬁtting a two-exponential function to the time
course of the deactivating tail currents. All data were expressed as
the mean7standard error. Statistical comparisons were made
using analysis of variance, followed by a t test, and the differences
were considered signiﬁcant at a value of Po0.05.
3. Results
3.1. Clinical features
Among our 355 probands with mutations in KCNQ1, KCNH2, or
SCN5A, 206 probands (58.0%) suffered cardiac events such as ventri-
cular arrhythmia or syncope. The average QTc interval of 355 probands
was 492.4755.7 ms. Fourteen probands (3.9%) carried a heterologous
KCNE1-D85N polymorphism. Coexisting mutations were identiﬁed in
either KCNQ1 or KCNH2 carriers. Ten mutations were missense, and
the remaining 4 were complex deletion/insertion mutations in KCNH2.
The average age of these subjects was 28718 years and females were
the dominant gender (n¼10, 71.4%). Eleven compound probands
carrying KCNE1-D85N were symptomatic (78.5%), while 195 probands
without KCNE1-D85N were symptomatic (57.1%, P¼0.17). The average
QTc interval of the probands with KCNE1-D85N was a little longer
(503.6792.7 ms) than that of probands without KCNE1-D85N
(491.8753.2 ms, P¼0.64). In 7 of 14 probands, we failed to conduct
genetic tests in their family members. In the remaining 7 families, we
found a family in which both genetic variants were found in multiple
family members (Fig. 1A). The proband (indicated by arrow in Fig. 1A)
was a 51-year-old woman who was admitted to the hospital because
of palpitations and repeated syncope. She experienced her ﬁrst
syncope at the age of 45. The standard 12-lead electrocardiogram
(ECG) showed a prolonged QT interval (QT/QTc, 478/490 ms; HR,
63 bpm), notched T waves in leads II, III, and aVF, and premature
ventricular contraction. Blood and serological tests showed normal
results. The echocardiogram, myocardial perfusion scintigraphy,
and coronary angiography with/without acetylcholine test were
all normal. Although ventricular ﬁbrillation was not inducible on
electrophysiological study, TdP with syncope was detected on the
ECG monitor while she was talking to her doctor. Because she showed
a marked sinus bradycardia (40 bpm) during the day, a pacemaker
was implanted and β-blocker therapy was started. Three uncles on her
maternal side underwent pacemaker implantation and an aunt died
suddenly before she reached 40-years-old (Fig. 1A).
The proband had 3 children (Fig. 1A), and her 2 sons were free
of symptoms with normal QTc intervals (QTc, 429 ms and 381 ms,
respectively). In contrast, her daughter experienced syncope
several times since she was 13 years old. When the daughter
was 22 years old, head-up tilt, exercise stress, and isoproterenol
challenge tests were performed to examine the cause of syncope
and she was suspected to have neurally mediated syncope.
However, she repeated syncope while micturition at the age of
27 and she consequently underwent Holter monitoring. Because
the ECG monitor demonstrated QT prolongation, she underwent
an epinephrine challenge test. Intravenous administration of
epinephrine (0.1 μg kg1 plus 0.1 μg kg1 min1) prolonged the
QT interval (QTc, 438 to 658 ms) and she was diagnosed
with LQTS.
3.2. Genetic analysis
DNA sequencing of the proband conﬁrmed a G to A transition
leading to amino acid substitution of aspartic acid for asparagine at
position 85 (D85N) located within the C-terminal region of KCNE1
(Fig. 1B-a) and a G to A transition leading to amino acid substitution of
glutamic acid for lysine at position 58 (E58K) in the N-terminus of
KCNH2 (Fig. 1B-b). We identiﬁed 2 heterozygous variants, KCNH2-E58K
and KCNE1-D85N, in the proband and her daughter. The proband's
elder son had KCNH2-E58K and the younger son had KCNE1-D85N,
respectively. In this family, therefore, a genetic double hit appeared to
largely modify the clinical phenotypes (Fig. 1A).
3.3. Biophysical assays
To examine the phenotype–genotype correlation, we ﬁrst
examined how the KCNH2-E58K mutation affected IKr currents
when reconstituted in CHO cells. Fig. 2 depicts 3 sets of typical
current traces recorded from cells transfected with KCNH2-WT
(A, 1 μg), KCNH2-WT/E58K (B, 0.5 μg each), and KCNH2-E58K (C,
1 μg). Cells transfected with KCNH2-WT displayed inwardly
Fig. 2. Functional expression analysis of KCNH2 in Chinese hamster ovary cells. Representative current traces of KCNH2 co-expression with the WT and/or E58K.
(A) KCNH2-WT (1 μg). (B) KCNH2-WT/E58K (0.5 μg of each). (C) KCNH2-E58K (1 μg).
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rectifying outward currents in response to depolarization pulses
and slowly deactivating tail currents (Fig. 2A). Cells transfected
with KCNH2-E58K alone produced very small outward currents
(Fig. 2C). Compared to KCNH2-WT, KCNH2-WT/E58K had reduced
peak tail currents by 25–28% at test potentials between 0 and
þ50 mV, although there was no statistical signiﬁcance. Moreover,
ﬁtting of normalized data to Boltzmann's equation yielded a V0.5 of
18.571.0 mV for KCNH2-WT and of 18.671.2 mV for KCNH2-
WT/E58K that were not signiﬁcantly different. Deactivation of tail
currents could be ﬁtted by 2 exponentials, yielding fast and slow
time constants (τfast and τslow). The deactivation time constants
were not signiﬁcantly different between the 2 current–voltage
relationships (Table 1). Taken together, the KCNH2 mutation
showed no apparent dominant negative suppression effects.
We then examined how KCNE1 and its D85N variant inﬂuence
the IKr currents. Fig. 3A-a and b depict 2 sets of current traces
recorded from CHO cells transfected with KCNH2-WT plus KCNE1-
WT or KCNE1-D85N (1 μg each). Lower panel c shows current
traces recorded from a cell transfected with KCNH2-WT and
KCNH2-E58K (0.5 μg each, total 1 μg) and KCNE1-D85N (1 μg),
which mimics the pathological condition of the index patients.
Peak tail current densities measured at 60mVwere calculated in
the respective cells and are plotted as a function of test potential in
Fig. 3B. Compared to KCNE1-WT, KCNE1-D85N reduced the peak tail
currents by 31–36% at test potentials between 0 and þ50mV
(Po0.005 vs. KCNH2-WT plus KCNE1-WT). KCNH2-WT/E58K plus
KCNE1-D85N reduced peak tail currents by 60–65% at test potentials
between 0 and þ50mV (Po0.0001 vs. KCNH2-WT plus KCNE1-WT).
Fitting of normalized data to Boltzmann's equation yielded a V0.5 of
18.370.8 mV for KCNH2-WT/KCNE1-WT, of 22.171.6 mV for
KCNH2-WT/KCNE1-D85N (Po0.05), and of 24.572.1 mV for
KCNH2-WT/E58K plus KCNE1-D85N (Po0.005). These data suggest
that the presence of both KCNH2-E58K and KCNE1-D85N caused a
signiﬁcantly negative shift of IKr activation kinetics (Fig. 3C and
Table 1). Fast and slow deactivation time constants (τfast and τslow)
were not signiﬁcantly different between the 2 types of IKr (Table 1).
4. Discussion
The present study provides clinical, molecular, and in vitro electro-
physiological evidence that a rare SNP (KCNE1-D85N) can act as a
genetic modiﬁer in LQTS. In general, SNPs are thought to be non-
pathological, but some have been reported to modify the clinical
features of the disease. For example, the KCNH2-K897T polymorphism
[8] has been shown to aggravate LQTS phenotypes directly by reducing
cardiac Kþ channel function in association with the KCNH2 mutation,
A1116V. The prevalence of the KCNH2-K897T polymorphism is esti-
mated to be up to 33% in Caucasians [10,12,13].
A rare genetic variant of LQTS, KCNE1-D85N, was originally
reported by Tesson et al. [14], and we have previously demonstrated
that the prevalence of the SNP is 0.8% in healthy Japanese individuals
and 3.9% in clinically diagnosed LQTS probands [9]. In a heterologous
expression system with Xenopus oocytes, KCNE1-D85N has been
shown to reduce IKs by approximately 50% [5]. In our previous
experiments [9] using CHO cells, D85N also signiﬁcantly reduced IKs
by 28% (Po0.05 vs. WT), although this was a smaller reduction than
that shown in Xenopus oocytes [5]. In contrast, when KCNH2-WT was
co-expressed with the variant, it was found to decrease IKr signiﬁcantly
by 31–36% (Po0.005 vs. WT) [9]. Regarding the current reduction, the
interaction between KCNE1 and KCNH2 was, therefore, stronger than
that between KCNE1 and KCNQ1. Since in the range of a normal heart
rate IKr plays a more essential role for ventricular repolarization than
IKs, carriers of loss-of-function KCNH2 mutations generally display
longer QT prolongation and bradycardia than those of KCNQ1
mutations.
The present study attests that 3.9% of the LQTS subjects genotyped
had the KCNE1-D85N variant in addition to a LQT-related mutation.
The average QT interval of KCNE1-D85N carriers was longer than that
of non-carriers. The incidence of symptoms in patients with KCNE1-
D85N was higher than that of the patients without KCNE1-D85N,
although the differences were not signiﬁcant. Here, we clinically
evaluated the family members as a group with a relatively homo-
geneous genetic background and/or the same mutation, KCNH2-E58K,
to show that the KCNE1-D85N polymorphism could act as a modiﬁer.
In fact, the proband and her daughter carried both KCNH2-E58K and
KCNE1-D85N and had a longer QT interval than the proband's son,
who carried KCNH2-E58K only. In a biophysical assay, KCNH2-WT/
E58K induced a small decrease in current densities, compared to
KCNH2-WT, suggesting no dominant negative suppression, but a small
mutant effect (Fig. 2). Co-expression of KCNH2-WT with/without
KCNH2-E58K and KCNE1-D85N showed a signiﬁcantly negative shift
of the activation curve compared to KCNH2-WT with KCNE1-WT
(6mV and 4mV, respectively); in other words, a gain of function.
However, there was a massive decrease in current densities by KCNE1-
D85N, about 60–65% (Po0.0001 vs. KCNH2-E58K and KCNE1-WT;
Fig. 3B). Therefore, the latter change led to a loss-of-function effect by
KCNE1-D85N. The proband and her daughter carried both these
2 genetic variants and both of them experienced TdP resulting in
repeated syncope. From these clinical features, the D85N variant was
suggested to aggravate the clinical phenotypes by largely reducing IKr.
Thus, loss-of-function effects caused by the combination of the
2 genetic variants may explain the signiﬁcant prolongation of the
QTc intervals and the severe symptoms in the family.
More recently, Yoshikane and his colleagues [15] reported a family
in which 2 genetic variants were harbored in the presence or absence
of the KCNE1-D85N polymorphism. They compared the symptoms
among the family members who carried one or more of the genetic
variants KCNH2-N45D, SCN5A-A1428S, or KCNE1-D85N. They demon-
strated that only the proband carrying all 3 variants (triple hit)
experienced ventricular ﬁbrillation, and his ECG showed marked
bradycardia. His brother and mother carried either KCNH2-N45D or
SCN5A-A1428S, in addition to KCNE1-D85N (double hit). His father
carried only KCNH2-N45D. All family members except for the proband
Table 1
V0.5, slope factor k and τ deactivation at þ20 mV.
N V0.5 k τfast τslow
KCNH2-WT 32 18.51570.961 9.37070.437 0.18470.008 1.09870.047
KCNH2-WT/E58K 34 18.59071.200 7.99370.309n 0.17470.010 1.05070.064
KCNH2-E58K 12 35.84772.060n 6.76670.506n 0.11870.024n 0.83470.141n
KCNH2-WTþKCNE1-WT 23 18.32670.775 7.37370.289 0.18370.016 1.07770.102
KCNH2-WTþKCNE1-D85N 20 22.06971.560nn 7.03770.389 0.19370.013 1.25870.090
KCNH2-WT/E58KþKCNE1-D85N 15 24.46772.122nnn 7.52570.947 0.21270.033 1.09270.149
n Po0.05 vs. KCNH2-WT.
nn Po0.05 vs. KCNH2-WTþKCNE1-WT.
nnn Po0.005 vs. KCNH2-WTþKCNE1-WT.
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remained asymptomatic. When compared, the phenotype of the
proband's brother and father (both carry KCNH2-N45D, but D85N is
present only in the brother), the QTc intervals were longer in the
brother (500 vs. 430 ms) and a Holter ECG revealed the presence of
bradycardia in the brother. Thus, KCNE1-D85N appeared to modify the
disease phenotypes, providing another example of D85N as a genetic
modiﬁer of LQTS.
In conclusion, a rare KCNE1-D85N polymorphism may modify
the LQTS phenotype in combination with other pathogenic LQTS-
related gene mutations.
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Fig. 3. Functional expression analysis of KCNH2 with KCNE1 in Chinese hamster ovary cells. A: Representative current traces of KCNH2 WT and/or E58K co-expression with
KCNE1-WT or KCNE1-D85N. (a) KCNH2-WT (1 μg) plus KCNE1-WT (1 μg). (b) KCNH2-WT (1 μg) plus KCNE1-D85N (1 μg) (Po0.005 vs. KCNH2-WT (1 μg) plus KCNE1-WT
(1 μg)). (c) KCNH2-WT/E58K (0.5 μg of each, total 1 μg) plus KCNE1-D85N (1 μg) (Po0.0001 vs. KCNH2-WT (1 μg) plus KCNE1-WT (1 μg)). (B and C) Functional consequences
of KCNH2WTand/or E58K with KCNE1-WT or D85N ([B] activation curve; [C] normalized activation curve). Solid circles indicate data from 23 cells that were transfected with
KCNH2-WT (1 μg) plus KCNE1-WT (1 μg). Solid triangles indicate data from 20 cells that were transfected with KCNH2-WT (1 μg) plus KCNE1-D85N (1 μg). Open squares
indicate data from 15 cells that were transfected with KCNH2-WT/E58K (0.5 μg each, total 1 μg) and KCNE1-D85N (1 μg).
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